利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.024 秒)

    Amorphous compound
    5.
    发明授权
    Amorphous compound 失效
    无定形化合物

    公开(公告)号：US06462174B1

    公开(公告)日：2002-10-08

    申请号：US09891035

    申请日：2001-06-25

    申请人： Ronald John Roberts

    发明人： Ronald John Roberts

    IPC分类号： C07K5087

    CPC分类号： C07K5/0222 ,  A61K38/00

    摘要： The present invention relates to a novel form of (S)-1-[N2-(1-carboxy-3-phenylpropyl]-L-lysyl]-L-proline known under the generic name lisinopril. Further, the present invention also relates to the use of the novel amorphous form of lisinopril for the treatment of hypertension and other cardiovascular diseases, pharmaceutical compositions containing it as well as processes for the preparation of the novel amorphous form of lisinopril.

    摘要翻译： 本发明涉及通用名义赖诺普公知的（S）-1- [N 2 - （1-羧基-3-苯基丙基] -L-赖氨酰] -L-脯氨酸的新型形式，本发明还涉及 使用赖诺普利的新型无定形形式用于治疗高血压和其他心血管疾病，含有它的药物组合物以及制备新型无定形形式的赖诺普利的方法。

    Amorphous compound
    6.
    发明授权
    Amorphous compound 失效

    公开(公告)号：US06458769B1

    公开(公告)日：2002-10-01

    申请号：US09891860

    申请日：2001-06-25

    申请人： Ronald John Roberts ,  John Brown

    发明人： Ronald John Roberts ,  John Brown

    IPC分类号： C07K506

    CPC分类号： C07K5/06086 ,  A61K38/00 ,  C07K5/022

    摘要： The present invention relates to a novel form of (S)-1-[N2-(1-carboxy-3-phenylpropyl]-L-lysyl]-L-proline known under the generic name lisinopril. Further, the present invention also relates to the use of the novel amorphous form of lisinopril for the treatment of hypertension and other cardiovascular diseases, pharmaceutical compositions containing it as well as processes for the preparation of the novel amorphous form of lisinopril.

    Lisinopril compositions having large-particle DCPD
    7.
    发明授权
    Lisinopril compositions having large-particle DCPD 有权
    赖诺普利组合物具有大颗粒DCPD

    公开(公告)号：US06462022B1

    公开(公告)日：2002-10-08

    申请号：US09962429

    申请日：2001-09-24

    申请人： Ronald John Roberts ,  David Brandon Bowen

    发明人： Ronald John Roberts ,  David Brandon Bowen

    IPC分类号： C07K5087

    CPC分类号： A61K38/556 ,  A61K9/2009

    摘要： The present invention relates to a pharmaceutical composition comprising lisinopril and dibasic calcium phosphate dihydrate (DCPD), produced by a process comprising mixing lisinopril and DCPD with a specific surface area of less than 1.5 m2g−1. The use of large particle sized DCPD in a lisinopril formulation/composition has the effect of reducing the amount of the lisinopril degradation product DKP that is formed, thereby increasing the shelf-life of tablets formulated with the larger sized DCPD, particularly those with low doses of lisinopril.

    摘要翻译： 本发明涉及包含赖诺普利和磷酸氢二钙二水合物（DCPD）的药物组合物，其通过包括混合赖诺普利和DCPD比表面积小于1.5m 2 / g的方法制备。 在赖诺普利制剂/组合物中使用大颗粒尺寸的DCPD具有减少形成的赖诺普利降解产物DKP的量的作用，从而增加用较大尺寸的DCPD配制的片剂的保质期，特别是低剂量的DCPD 的赖诺普利。

    Amorphous compound
    8.
    发明授权
    Amorphous compound 失效
    无定形化合物

    公开(公告)号：US06627760B1

    公开(公告)日：2003-09-30

    申请号：US09891190

    申请日：2001-06-25

    申请人： Ronald John Roberts

    发明人： Ronald John Roberts

    IPC分类号： C07D20720

    CPC分类号： C07D207/20

    摘要： The present invention relates to a novel form of (S)-1-[N2-(1-carboxy-3-phenylpropyl]-L-lysyl]-L-proline known under the generic name lisinopril. Further, the present invention also relates to the use of the novel amorphous form of lisinopril for the treatment of hypertension and other cardiovascular diseases, pharmaceutical compositions containing it as well as processes for the preparation of the novel amorphous form of lisinopril.

    摘要翻译： 本发明涉及以通用名义赖诺普公知的（S）-1- [N 2 - （1-羧基-3-苯基丙基] -L-赖氨酰] -L-脯氨酸的新型形式，此外，本发明 本发明还涉及新兴无定形形式的赖诺普利用于治疗高血压和其他心血管疾病，含有它的药物组合物以及制备新型无定形形式的赖诺普利的方法。